

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai Haohai Biological Technology Co., Ltd.\***

**上海昊海生物科技股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6826)**

**SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE  
ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2018**

Reference is made to the announcement of Shanghai Haohai Biological Technology Co., Ltd. (the “**Company**”) dated 14 March 2019 in relation to the annual results of the Company for the year ended 31 December 2018 (the “**Announcement**”). The board of directors of the Company (the “**Board**”) hereby announces that the Board does not recommend the payment of a final dividend to the shareholders of the Company for the year ended 31 December 2018.

This supplemental announcement is supplemental to and should be read in conjunction with the Announcement.

By order of the Board  
**Shanghai Haohai Biological Technology Co., Ltd.\***  
**Hou Yongtai**  
*Chairman*

Shanghai, the PRC, 15 March 2019

*As at the date of this announcement, the executive directors of the Company are Dr. Hou Yongtai, Mr. Wu Jianying, Mr. Huang Ming, Ms. Chen Yiyi and Mr. Tang Minjie; the non-executive directors of the Company are Ms. You Jie and Mr. Gan Renbao; and the independent non-executive directors of the Company are Mr. Chen Huabin, Mr. Shen Hongbo, Mr. Li Yuanxu, Mr. Zhu Qin and Mr. Wong Kwan Kit.*

\* *For identification purpose only*